Science to Market
Preventative medicine
Longevity science
regenerative therapies
Preventative medicine
Longevity science
regenerative therapies
Opening markets across Europe and Asia Pacific for Healthspan innovations
with a point of view and skin in the game.
Opening markets across Europe and Asia Pacific for Healthspan innovations
with a point of view and skin in the game.
"The science is ready. The people who need it are waiting. The path between them is where we work."
market Entry - Science to market - bd & partnerships - hands-on advisorY
STRATEGIC ADVISORY
If the world needs your science, we'll build the path.
If the world needs your science, we'll build the path.
We Turn Science Into Market Reality
Manifesto
Manifesto
We know what it feels like to watch brilliant science stop short of its full potential. That's why we go beyond strategy — into the field, the meetings, the market, until the path is real.
No documents handed over and forgotten. No generic frameworks. Just deep scientific fluency, genuine cultural intelligence, and the kind of execution that turns innovation into adoption — so the right science reaches the right humans.
We know what it feels like to watch brilliant science stop short of its full potential. That's why we go beyond strategy — into the field, the meetings, the market, until the path is real.
No documents handed over and forgotten. No generic frameworks. Just deep scientific fluency, genuine cultural intelligence, and the kind of execution that turns innovation into adoption — so the right science reaches the right humans.
Market Entry Diagnostics
Choosing the right market for your innovation, at the right moment — before you commit resources, relationships, and momentum to the wrong one.
Market Entry Diagnostics
Choosing the right market for your innovation, at the right moment — before you commit resources, relationships, and momentum to the wrong one.
Market Entry Diagnostics
Choosing the right market for your innovation, at the right moment — before you commit resources, relationships, and momentum to the wrong one.
Science to Market
Translating complex science into commercial opportunities — so your innovation speaks the language of every room it needs to enter.
Science to Market
Translating complex science into commercial opportunities — so your innovation speaks the language of every room it needs to enter.
Science to Market
Translating complex science into commercial opportunities — so your innovation speaks the language of every room it needs to enter.
BD & Partnerships
Opening the right doors in the right markets — with the relationships and scientific credibility to make every introduction count.
BD & Partnerships
Opening the right doors in the right markets — with the relationships and scientific credibility to make every introduction count.
BD & Partnerships
Opening the right doors in the right markets — with the relationships and scientific credibility to make every introduction count.
Hands-On Advisory
Senior strategic guidance and execution support — embedded with your team, responsive to the pace of your expansion.
Hands-On Advisory
Senior strategic guidance and execution support — embedded with your team, responsive to the pace of your expansion.
Hands-On Advisory
Senior strategic guidance and execution support — embedded with your team, responsive to the pace of your expansion.
Entered Europe with a Clear Market Sequence
Japanese diagnostics company
Diagnostics
2025
Entered Europe with a Clear Market Sequence
Japanese diagnostics company
Diagnostics
2025
Entered Europe with a Clear Market Sequence
Diagnostics
2025
€5M+ in Distribution Agreements
German medtech scale-up
Medical Devices
2024
€5M+ in Distribution Agreements
German medtech scale-up
Medical Devices
2024
€5M+ in Distribution Agreements
Medical Devices
2024
First French Distribution Deal Signed in 10 Weeks
Korean nutraceuticals brand
Nutraceuticals
2026
First French Distribution Deal Signed in 10 Weeks
Korean nutraceuticals brand
Nutraceuticals
2026
First French Distribution Deal Signed in 10 Weeks
Nutraceuticals
2026
European Partnerships
Korean biotech
Biotech
2026
European Partnerships
Korean biotech
Biotech
2026
European Partnerships
Biotech
2026
Europe is not one market. DSA helped us identify which countries to enter first and built a distinct positioning for each — that strategic clarity alone saved us years of costly trial and error.
Hiroshi Y.
CCO, Japanese diagnostics company
DSA understood our science without needing to be briefed. They connected us with the right European partners and helped structure the deal — that end-to-end BD support is rare and genuinely hard to find.
Josh O.
CSO, UK-based drug discovery startup
We had strong clinical evidence but couldn't make it land commercially. DSA translated our science into a market story buyers actually responded to — and mapped the regulatory path that made entry real.
Thomas M.
CEO, German medtech scale-up
We had strong data but no roadmap for Europe. DSA didn't just advise us — they were in the room. Within four months we had two serious partnership conversations underway.
Soo-Yeon K
Co-founder, South Korean biotech startup
Selling AI into preventative health requires clinical credibility, not just a good product. DSA connected us with the right KOLs in each market — those introductions changed how seriously we were taken.
Nikhil P.
CEO, Ireland-based healthtech startup
The European market was opaque to us. DSA mapped the landscape, got us in front of the right distribution partners, and stayed with us through to the deal. Not advisory at a distance — genuinely in it with us.
Ji-won H.
Founder, South Korean nutraceuticals brand
Europe is not one market. DSA helped us identify which countries to enter first and built a distinct positioning for each — that strategic clarity alone saved us years of costly trial and error.
Hiroshi Y.
CCO, Japanese diagnostics company
DSA understood our science without needing to be briefed. They connected us with the right European partners and helped structure the deal — that end-to-end BD support is rare and genuinely hard to find.
Josh O.
CSO, UK-based drug discovery startup
We had strong clinical evidence but couldn't make it land commercially. DSA translated our science into a market story buyers actually responded to — and mapped the regulatory path that made entry real.
Thomas M.
CEO, German medtech scale-up
We had strong data but no roadmap for Europe. DSA didn't just advise us — they were in the room. Within four months we had two serious partnership conversations underway.
Soo-Yeon K
Co-founder, South Korean biotech startup
Selling AI into preventative health requires clinical credibility, not just a good product. DSA connected us with the right KOLs in each market — those introductions changed how seriously we were taken.
Nikhil P.
CEO, Ireland-based healthtech startup
The European market was opaque to us. DSA mapped the landscape, got us in front of the right distribution partners, and stayed with us through to the deal. Not advisory at a distance — genuinely in it with us.
Ji-won H.
Founder, South Korean nutraceuticals brand
0+
0+
projects completed
projects completed
0
0
countries covered
countries covered
0
0
mission - science that reaches people
mission - science that reaches people
0
0
vanity metrics — only real outcomes
vanity metrics — only real outcomes
Kahina BELAID — FoundER & DIRECTOR
Kahina BELAID — FoundER & DIRECTOR
About
About
I've never believed the human body is built to decline. What led me to found Deep Science Advisor was watching extraordinary science fall short — not for lack of evidence, but for lack of a path to market.
I'm an entrepreneur first, I've built from zero, taken the risk, felt the gaps. What senior roles at J&J, Merck, and Roche added was a different kind of education — the internal logic of large organisations, how science has to demonstrate commercial viability before it earns the right to move.
Trained as a Biotech and Pharmacology Engineer with a Master's from HEC Paris, I've lived across 14 cities on 4 continents and raised two daughters in different cultures. Three citizenships later, I'm currently learning Korean and Japanese, because I believe real cultural fluency builds with language.
I bring that same rigour to the science of my own body , tracking biomarkers, training for VO2 max, following the evidence as both pharmacologist and practitioner. How I live is inseparable from how I think — that's not a lifestyle statement, it's how I stay ahead of the science I advise on.
Wherever the future
of health is
being shaped
Wherever the future
of health is
being shaped
IN THE FIELD
IN THE FIELD
These are the rooms where science is showcased, deals get initiated, partnerships advance, and longevity innovation finds its next market. DSA is present at each one — if you're attending, let's make the time count.
These are the rooms where science is showcased, deals get initiated, partnerships advance, and longevity innovation finds its next market. DSA is present at each one — if you're attending, let's make the time count.
Longevity Med Summit
9–10 May 2026 London, UK
Longevity Summit Dublin
24–26 Jun 2026 Dublin, Ireland
Korea Life Science Week
21–22 Sep 2026 Seoul, South Korea
BioJapan RegenerativeMedicine
7–9 Oct 2026 Yokohama, Japan
BIO-Europe
9–11 Nov 2026 Cologne, Germany
Longevity Med Summit
9–10 May 2026 London, UK
Longevity Summit Dublin
24–26 Jun 2026 Dublin, Ireland
Korea Life Science Week
21–22 Sep 2026 Seoul, South Korea
BioJapan RegenerativeMedicine
7–9 Oct 2026 Yokohama, Japan
BIO-Europe
9–11 Nov 2026 Cologne, Germany
Longevity Med Summit
9–10 May 2026 London, UK
Longevity Summit Dublin
24–26 Jun 2026 Dublin, Ireland
Korea Life Science Week
21–22 Sep 2026 Seoul, South Korea
BioJapan RegenerativeMedicine
7–9 Oct 2026 Yokohama, Japan
BIO-Europe
9–11 Nov 2026 Cologne, Germany
Simple steps, no extra layers
Simple steps, no extra layers
How it works
How it works
1
Introductory Call
Introductory Call
We start with a conversation to understand your science, your target market, and where you are in the journey. No strings attached.
We start with a conversation to understand your science, your target market, and where you are in the journey. No strings attached.
2
The Diagnostic
The Diagnostic
A focused engagement to assess your innovation, commercial positioning, and market readiness. You get a clear, honest picture of what needs to happen — and a plan that's actually executable.
A focused engagement to assess your innovation, commercial positioning, and market readiness. You get a clear, honest picture of what needs to happen — and a plan that's actually executable.
3
Into the Field
Into the Field
We go into the market alongside you — meeting partners, navigating regulatory pathways, building relationships, and staying until the work lands. No handover. No stepping back.
We go into the market alongside you — meeting partners, navigating regulatory pathways, building relationships, and staying until the work lands. No handover. No stepping back.
FAQ. Straight Answers
FAQ. Straight Answers
No jargon, no fluff — just clear answers to the questions we hear most from founders and teams considering working with DSA.
No jargon, no fluff — just clear answers to the questions we hear most from founders and teams considering working with DSA.
Which markets do you work in?
DSA specialises in market entry and go-to-market strategy between Europe and Asia Pacific — specifically the UK, EU Big 4, Switzerland, the Nordics, Singapore, Japan, and South Korea. These are not markets we advise on from a distance. We operate on the ground, with the networks and cultural fluency that come from years of working there.
Which sectors do you work in?
How long does a typical engagement take?
Do you work with early-stage companies?
What do you need from us to get started?
Which markets do you work in?
DSA specialises in market entry and go-to-market strategy between Europe and Asia Pacific — specifically the UK, EU Big 4, Switzerland, the Nordics, Singapore, Japan, and South Korea. These are not markets we advise on from a distance. We operate on the ground, with the networks and cultural fluency that come from years of working there.
Which sectors do you work in?
How long does a typical engagement take?
Do you work with early-stage companies?
What do you need from us to get started?